
    
      The primary hypothesis of this study is that subcutaneous Daratumumab in combination with
      Lenalidomide will prolong progression-free survival and likely induce less toxicity as
      compared with Lenalidomide and dexamethasone, in elderly frail subjects with newly diagnosed
      Multiple myeloma who are ineligible for high dose chemotherapy and ASCT
    
  